Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.
Has real earnings that are identifiable. Could see them making $0.35US this year and growing to $0.80US next year. Market share is back again in spite of the recall troubles they experienced. Looking to diversify the stent further away from the heart.
(A Top Pick in March/04.) Still likes. Thinks the market in tissue has bottomed out and expects stronger prices going forward. Margins in container board is improving. Book value is almost $13. Cyclical.
(A Top Pick in March/04.) Still likes. Thinks the market in tissue has bottomed out and expects stronger prices going forward. Margins in container board is improving. Book value is almost $13. Cyclical.